Therapeutic targeting of the mitotic spindle checkpoint through nanoparticle-mediated siRNA delivery inhibits tumor growth in vivo

Cancer Letters

Volumn 304, Issue 2, 2011, Pages 128-136

  Kaestner, Phillip ^a   Aigner, Achim ^b   Bastians, Holger ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Cancer therapy; Cell cycle; Mitosis; Polyethylenimine; RNAi

Indexed keywords

NANOPARTICLE; POLYETHYLENEIMINE; PROTEIN MAD2; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL STRAIN HCT116; CHROMOSOME SEGREGATION; COLON CARCINOMA; CONTROLLED STUDY; DRUG TARGETING; GENE; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAD2 GENE; MITOSIS SPINDLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; SOLID TUMOR; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CALCIUM-BINDING PROTEINS; CELL CYCLE PROTEINS; CELL SEPARATION; FLOW CYTOMETRY; GENE THERAPY; HCT116 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; MITOTIC SPINDLE APPARATUS; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; POLYETHYLENEIMINE; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 79952735387     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.02.014     Document Type: Article

References (27)

1. Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 2004, 4:253-265.
2. Schmidt M., Bastians H. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist. Update. 2007, 10:162-181.
3. Kaestner P., Bastians H. Mitotic drug targets. J. Cell. Biochem. 2010, 111:258-265.
4. Stolz A., Vogel C., Schneider V., Ertych N., Kienitz A., Yu H., Bastians H. Pharmacologic abrogation of the mitotic spindle checkpoint by an indolocarbazole discovered by cellular screening efficiently kills cancer cells. Cancer Res. 2009, 69:3874-3883.
5. Bolanos-Garcia V.M. Assessment of the mitotic spindle assembly checkpoint (SAC) as the target of anticancer therapies. Curr. Cancer Drug Targets 2009, 9:131-141.
6. Musacchio A., Salmon E.D. The spindle-assembly checkpoint in space and time. Nat. Rev. Mol. Cell Biol. 2007, 8:379-393.
7. Hanks S., Coleman K., Reid S., Plaja A., Firth H., Fitzpatrick D., Kidd A., Mehes K., Nash R., Robin N., Shannon N., Tolmie J., Swansbury J., Irrthum A., Douglas J., Rahman N. Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nat. Genet. 2004, 36:1159-1161.
8. Wang X., Jin D.Y., Ng R.W., Feng H., Wong Y.C., Cheung A.L., Tsao S.W. Significance of MAD2 expression to mitotic checkpoint control in ovarian cancer cells. Cancer Res. 2002, 62:1662-1668.
9. Cahill D.P., Lengauer C., Yu J., Riggins G.J., Willson J.K., Markowitz S.D., Kinzler K.W., Vogelstein B. Mutations of mitotic checkpoint genes in human cancers. Nature 1998, 392:300-303.
10. Takahashi T., Haruki N., Nomoto S., Masuda A., Saji S., Osada H., Takahashi T. Identification of frequent impairment of the mitotic checkpoint and molecular analysis of the mitotic checkpoint genes, hsMAD2 and p55CDC, in human lung cancers. Oncogene 1999, 18:4295-4300.
11. Dobles M., Liberal V., Scott M.L., Benezra R., Sorger P.K. Chromosome missegregation and apoptosis in mice lacking the mitotic checkpoint protein Mad2. Cell 2000, 101:635-645.
12. Michel L.S., Liberal V., Chatterjee A., Kirchwegger R., Pasche B., Gerald W., Dobles M., Sorger P.K., Murty V.V., Benezra R. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 2001, 409:355-359.
13. Michel L., Diaz-Rodriguez E., Narayan G., Hernando E., Murty V.V., Benezra R. Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc. Natl. Acad. Sci. USA 2004, 101:4459-4564.
14. Kops G.J., Foltz D.R., Cleveland D.W. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc. Natl. Acad. Sci. USA 2004, 101:8699-8704.
15. DeMoe J.H., Santaguida S., Daum J.R., Musacchio A., Gorbsky G.J. A high throughput, whole cell screen for small molecule inhibitors of the mitotic spindle checkpoint identifies OM137, a novel Aurora kinase inhibitor. Cancer Res. 2009, 69:1509-1516.
16. Kaestner P., Stolz A., Bastians H. Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol. Cancer Ther. 2009, 8:2046-2056.
17. Aigner A. Nonviral in vivo delivery of therapeutic small interfering RNAs. Curr. Opin. Mol. Ther. 2007, 9:345-352.
18. Urban-Klein B., Werth S., Abuharbeid S., Czubayko F., Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 2005, 12:461-466.
19. Hobel S., Koburger I., John M., Czubayko F., Hadwiger P., Vornlocher H.P., Aigner A. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J. Gene Med. 2010, 12:287-300.
20. Kienitz A., Vogel C., Morales I., Muller R., Bastians H. Partial downregulation of MAD1 causes spindle checkpoint inactivation and aneuploidy, but does not confer resistance towards taxol. Oncogene 2005, 24:4301-4310.
21. Vogel C., Hager C., Bastians H. Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation. Cancer Res. 2007, 67:339-345.
22. Aigner A., Ray P.E., Czubayko F., Wellstein A. Immunolocalization of an FGF-binding protein reveals a widespread expression pattern during different stages of mouse embryo development. Histochem. Cell Biol. 2002, 117:1-11.
23. Taylor S.S., Hussein D., Wang Y., Elderkin S., Morrow C.J. Kinetochore localisation and phosphorylation of the mitotic checkpoint components Bub1 and BubR1 are differentially regulated by spindle events in human cells. J. Cell Sci. 2001, 114:4385-4395.
24. Vogel C., Kienitz A., Hofmann I., Muller R., Bastians H. Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy. Oncogene 2004, 23:6845-6853.
25. Grzelinski M., Urban-Klein B., Martens T., Lamszus K., Bakowsky U., Hobel S., Czubayko F., Aigner A. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum. Gene Ther. 2006, 17:751-766.
26. Chen J.G., Horwitz S.B. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res. 2002, 62:1935-1938.
27. Janssen A., Kops G.J., Medema R.H. Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proc. Natl. Acad. Sci. USA 2009, 106:19108-19113.